G Barbara1, Z Xing, C M Hogaboam, J Gauldie, S M Collins. 1. The Intestinal Disease Research Program, Division of Gastroenterology, Departments of Medicine and Pathology, McMaster University Faculty of Health Sciences, Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada.
Abstract
BACKGROUND: The development of colitis in interleukin 10 (IL-10) deficient mice, together with the known anti-inflammatory and immunomodulatory properties of this cytokine have prompted consideration of IL-10 as a treatment for inflammatory bowel disease (IBD). However, studies using hrIL-10 in IBD models have yielded inconsistent results. AIMS: To examine the therapeutic potential of overexpressing the IL-10 gene before and after the induction of experimental colitis in rats. METHODS: Gene transfer was achieved by intraperitoneal injection of non-replicating human type 5 adenovirus bearing the IL-10 gene, either 24 hours before or one hour after intrarectal administration of dinitrobenzene sulphonic acid in rats. Colonic damage and inflammation was assessed macroscopically and by measuring myeloperoxidase activity and leukotriene B4 concentrations. RESULTS: Gene transfer increased IL-10 protein in serum for up to six days. IL-10 gene transfer prior to colitis improved colitis macroscopically and histologically, and significantly reduced colonic myeloperoxidase activity and leukotriene B4 concentrations. In contrast, IL-10 gene transfer after the onset of colitis had no beneficial effect. CONCLUSIONS: Gene therapy using an adenovirus-IL-10 construct was successful in preventing but not in reversing experimental colitis in the rat.
BACKGROUND: The development of colitis in interleukin 10 (IL-10) deficient mice, together with the known anti-inflammatory and immunomodulatory properties of this cytokine have prompted consideration of IL-10 as a treatment for inflammatory bowel disease (IBD). However, studies using hrIL-10 in IBD models have yielded inconsistent results. AIMS: To examine the therapeutic potential of overexpressing the IL-10 gene before and after the induction of experimental colitis in rats. METHODS: Gene transfer was achieved by intraperitoneal injection of non-replicating human type 5 adenovirus bearing the IL-10 gene, either 24 hours before or one hour after intrarectal administration of dinitrobenzene sulphonic acid in rats. Colonic damage and inflammation was assessed macroscopically and by measuring myeloperoxidase activity and leukotriene B4 concentrations. RESULTS: Gene transfer increased IL-10 protein in serum for up to six days. IL-10 gene transfer prior to colitis improved colitis macroscopically and histologically, and significantly reduced colonic myeloperoxidase activity and leukotriene B4 concentrations. In contrast, IL-10 gene transfer after the onset of colitis had no beneficial effect. CONCLUSIONS: Gene therapy using an adenovirus-IL-10 construct was successful in preventing but not in reversing experimental colitis in the rat.
Authors: D J Berg; N Davidson; R Kühn; W Müller; S Menon; G Holland; L Thompson-Snipes; M W Leach; D Rennick Journal: J Clin Invest Date: 1996-08-15 Impact factor: 14.808
Authors: G Piedimonte; R J Pickles; J R Lehmann; D McCarty; D L Costa; R C Boucher Journal: Am J Respir Cell Mol Biol Date: 1997-03 Impact factor: 6.914
Authors: Halide Tuna; Rita G Avdiushko; Vishal J Sindhava; Leia Wedlund; Charlotte S Kaetzel; Alan M Kaplan; Subbarao Bondada; Donald A Cohen Journal: J Leukoc Biol Date: 2013-12-02 Impact factor: 4.962
Authors: A Nakao; B A Moore; N Murase; F Liu; B S Zuckerbraun; F H Bach; A M K Choi; M A Nalesnik; L E Otterbein; A J Bauer Journal: Gut Date: 2003-09 Impact factor: 23.059
Authors: P Trittibach; S E Barker; C A Broderick; M Natkunarajah; Y Duran; S J Robbie; J W B Bainbridge; A J Smith; G-M Sarra; A D Dick; R R Ali Journal: Gene Ther Date: 2008-06-26 Impact factor: 5.250